中华眼底病杂志

中华眼底病杂志

葡萄膜黑色素瘤放射治疗后继发放射性视网膜病变的干预治疗研究现状

查看全文

放射治疗(放疗)是葡萄膜黑色素瘤的首选治疗,但以放射性视网膜病变为首的放疗并发症,是导致患者远期视力丧失和二次眼球摘除的最常见原因。虽然目前治疗手段多样,但优势治疗难以定论且缺乏规范治疗策略。近年对抗血管内皮生长因子药物和糖皮质激素类药物的应用观察成为研究热点,现就针对葡萄膜黑色素瘤继发放射性视网膜病变的各种干预治疗手段及其现状进行综述。

Radiotherapy is the prior treatment for uveal melanoma, but a major problem confronted most of the patients is radiation retinopathy, which accompanied with severe visual loss and secondary enucleation potential. There is no optium choice and normative strategy so far, the intraocular melanoma society has focused on application of anti-vascular endothelial growth factor drugs injection and glucocorticoids. This article reviews a series of potential managements for radiation retinopathy and its further stage .

关键词: 葡萄膜肿瘤/放射疗法; 放射疗法/副作用; 视网膜疾病/治疗; 综述

Key words: Uveal neoplasms/radiotherapy; Radiotherapy/adverse effects; Retinal diseases/therapy; Review

引用本文: 陈梦曦, 刘月明, 魏文斌. 葡萄膜黑色素瘤放射治疗后继发放射性视网膜病变的干预治疗研究现状. 中华眼底病杂志, 2018, 34(5): 515-518. doi: 10.3760/cma.j.issn.1005-1015.2018.05.025 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. 王光璐, 魏文斌, 蔡善钰, 等. 脉络膜黑色素瘤敷贴放射治疗的初步观察[J]. 中华眼底病杂志, 2006, 22(3):157-160.Wang GL, Wei WB, Cai SY, et al.Priliminary observation on choroidal melanoma treated by plaque radiotherapy[J]. Chin J Ocul Fundus Dis, 2006, 22(3):157-160.
2. Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. Visual acuity after 3 years COMS report no.16[J]. Ophthalmology, 2001, 108(2): 348-366.
3. Matet A, Daruich A, Zografos L. Radiation maculopathy after proton beam therapy for uveal melanoma: optical coherence tomography angiography alterations influencing visual acuity[J]. Invest Ophthalmol Vis Sci, 2017, 58(10):3851-3861.DOI: 10.1167/iovs.17-22324.
4. Bianciotto C, Shields CL, Pirondini C. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma[J]. Ophthalmology, 2010, 117(5):1005-1012. DOI: 10.1016/j.ophtha.2009.10.015.
5. Horgan N, Shields CL, Mashayekhi A, et al.Classification and treatment of radiation maculopathy[J]. Curr Opin Ophthalmol, 2010, 21(3):233-238. DOI: 10.1097/ICU.0b013e3283386687.
6. Horgan N, Shields CL, Mashayekhi A, et al.Early macular morphological changes following plaque radiotherapy for uveal melanoma[J]. Retina, 2008, 28(2):263-273.
7. Bianciotto C, Shields CL, Pirondini C, et al.Vitreous hemorrhage after plaque radiotherapy for uveal melanoma[J]. Retina, 2012, 32(6):1156-1164.DOI:10.1097/IAE.0b013e3182340cc1.
8. Kinyoun JL.Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis)[J]. Trans Am Ophthalmol Soc, 2008, 106:325-335.
9. Materin MA, Bianciotto CG, Wu C, et al.Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study[J]. Retina, 2012, 32(8):1601-1607.DOI: 10.1097/IAE.0b013e3182437e70.
10. Shah NV, Houston SK, Markoe AM, et al.Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity[J]. Clin Ophthalmol, 2012, 6:1739-1748.DOI: 10.2147/OPTH.S34949.
11. Finger PT, Chin KJ, Semenova EA. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study[J]. Eur J Ophthalmol, 2016, 26(1):60-66. DOI: 10.5301/ejo.5000670.
12. Reichstein D.Current treatments and preventive strategies for radiation retinopathy[J]. Curr Opin Ophthalmol, 2015, 26(3):157-166.DOI: 10.1097/ICU.0000000000000141.
13. Mahdjoubi A, Najean M, Lemaitre S, et al. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy[J]. Graefe’s Arch Clin Exp Ophthalmol, 2018, 256(2):411-420.DOI:10.1007/s00417-017-3834-3.
14. Hurtikova K, Gerding H.Combined laser photocoagulation and anti-VEGF injection treatment in radiation retinopathy[J]. Klin Monbl Augenheilkd, 2017, 234(5): 515-519.DOI:10.1055/s-0042-123165.
15. Shields CL, Demirci H, Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma[J]. Retina, 2005, 25 (7): 868-874.
16. Shah NV, Houston SK, Markoe A, et al.Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma[J]. Clin Ophthalmol, 2013, 7:1877-1882. DOI: 10.2147/OPTH.S47684.
17. Bui KM, Chow CC, Mieler WF. Treatment of recalcitrant radiation maculopathy using intravitreal dexamethasone (Ozurdex) implant[J]. Retin Cases Brief Rep, 2014, 8(3): 167- 170.DOI: 10.1097/ICB.0000000000000032.
18. Frizziero L, Parrozzani R, Trainiti S, et al. Intravitreal dexamethasone implant in radiation-induced macular oedema[J]. Br J Ophthalmol, 2017, 101(12):1699-1703. DOI: 10.1136/bjophthalmol-2017-310220.
19. Russo A, Reibaldi M, Avitabile T, et al. Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma[J/OL]. Retina, 2017, 2017:E1[2017-03-07]. https://insights.ovid.com/pubmed?pmid=28272283. DOI:10.1097/IAE.0000000000001585.[published online ahead of print].
20. Caminal JM, Flores-Moreno I, Arias L, et al. Intravitreal dexamethasone implant for radiation maculopathy secondary to plaque brachytherapy in choroidal melanoma[J]. Retina, 2015, 35(9):1890-1897.DOI:10.1097/IAE.0000000000000537.
21. Koc I, Kadayifcilar S, Kiratli H, et al. Intravitreal dexamethasone (Ozurdex) implant for radiation maculopathy secondary to stereotactic radiotherapy for posterior uveal melanoma[J/OL]. Retin Cases Brief Rep, 2017, 2017:E1[2017-05-09]. https://insights.ovid.com/pubmed?pmid=28489707. DOI: 10.1097/ICB.0000000000000593.[published online ahead of print].
22. Finger PT. Radiation retinopathy is treatable with antivascular endothelial growth factor bevacizumab (Avastin)[J]. Int J Radiat Oncol Biol Phys, 2008, 70(4):974-977. DOI: 10.1016/j.ijrobp.2007.11.045.
23. Seibel I, Hager A, Riechardt AI, et al. Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma[J]. Am J Ophthalmol, 2016, 168:31-39.DOI: 10.1016/j.ajo.2016.04.024.
24. Pagliara MM, Tagliaferri L, Azario L, et al. Ruthenium brachytherapy for uveal melanomas: factors affecting the development of radiation complications[J]. Brachytherapy, 2018, 17(2):432-438.DOI: 10.1016/j.brachy.2017.11.004.
25. Mashayekhi A, Schönbach E, Shields CL, et al. Early subclinical macular edema in eyes with uveal melanoma: association with future cystoid macular edema[J]. Ophthalmology, 2015, 122(5):1023-1029.DOI: 10.1016/j.ophtha.2014.12.034.
26. Bakri SJ, Larson TA.The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy[J]. Semin Ophthalmol, 2015, 30(4):276-280.DOI:10.3109/08820538.2013.847110.
27. Chia SN, Smith HB, Hammer HM, et al.Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland[J]. Eye (Lond), 2015, 29(6):748-756.DOI: 10.1038/eye.2015.20.
28. Mccannel TA, Kamrava M, Demanes J, et al. 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity[J]. Graefe’s Arch Clin Exp Ophthalmol, 2016, 254(12):2461-2467.DOI:10.1007/s00417-016-3485-9.
29. Riechardt AI, Cordini D, Rehak M, et al. Trabeculectomy in patients with uveal melanoma after proton beam therapy[J]. Graefe’s Arch Clin Exp Ophthalmol, 2016, 254 (7):1379-1385. DOI:10.1007/s00417-016-3310-5.
30. Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma[J]. Retina, 2008, 28(7):987-995.DOI: 10.1097/IAE.0b013e31816b3192.
31. Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial[J]. Ophthalmology, 2009, 116(7):1383-1390.DOI:10.1016/j.ophtha.2009.01.051.
32. Shah SU, Shields CL, Bianciotto CG, et al.Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma[J]. Ophthalmology, 2014, 121(1):269-275. DOI:10.1016/j.ophtha.2013.08.039.
33. Haji Mohd Yasin NA, Gray AR, Bevin TH, et al. Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: the Dunedin hospital experience[J]. J Med Imag Health In, 2016, 60(6):756-763.
34. Li J, Cui Y, Wang Q, et al. The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1[J]. Mol Vis, 2014, 20(236):649-660.
35. Krema H, Somani S, Sahgal A, et al. Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up[J]. Br J Ophthalmol, 2009, 93(9):1172- 1176.DOI: 10.1136/bjo.2008.153429.
36. Oliver SC, Leu MY, Demarco JJ, et al. Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma[J]. Arch Ophthalmol, 2010, 128(7):888-893. DOI:10.1001/archophthalmol.2010.117.
37. Mccannel TA, Mccannel CA. Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series[J]. Int J Radiat Oncol Biol Phys, 2014, 89(2):347-352.DOI: 10.1016/j.ijrobp.2014.02.021.
38. Aziz HA, Singh N, Bena J, et al. Vision loss following episcleral brachytherapy for uveal melanoma: development of a vision prognostication tool[J]. JAMA Ophthalmol, 2016, 134(6): 615-620.DOI:10.1001/jamaophthalmol.2016.0104.